Prediction of Overall Survival of Patients with Completely Resected Non-Small Cell Lung Cancer: Analyses of Preoperative Spirometry, Preoperative Blood Tests, and Other Clinicopathological Data

Mengkun Shi1
Cheng Zhan2
Jialun Shi3
Qun Wang2
1Department of Oncology, The Affiliated Heping Hospital of Changzhi Medical College, Changzhi City, Shanxi Province, People’s Republic of China; 2Department of Thoracic Surgery, ZhongShan Hospital, Fudan University, Shanghai, People’s Republic of China; 3Department of Thoracic Surgery, The Affiliated Heping Hospital of Changzhi Medical College, Changzhi City, Shanxi Province, People’s Republic of China

Purpose: Risk stratification of patients with non-small cell lung cancer (NSCLC) is crucial to select the appropriate treatments, but available models for patients with complete resection are unsatisfactory. The purpose of this study was to determine a prediction model based on clinical information, routine physical and blood tests, and molecular markers.

Patients and Methods: This was a retrospective cohort study of patients who underwent surgical resection for lung cancer between 2009 to 2013. Potential prognostic factors were used to build a full prediction model based on a multivariable Cox regression analysis. A nomogram was constructed. The risk stratification cutoffs for clinical use were determined based on the model.

Results: A total of 368 NSCLC patients with R0 resection were included. The final multivariable model indicated that low diffusing capacity of the lung for carbon monoxide (HR=1.66, 95% CI: 1.18–2.34), high platelet-to-lymphocyte ratio (HR=1.42, 95% CI: 1.04–1.95), histology type of squamous cell carcinoma and others (squamous cell carcinoma vs adenocarcinoma, HR=1.40, 95% CI: 1.01–1.96; others vs adenocarcinoma, HR=2.36, 95% CI: 1.15–4.84; \( P \) trend=0.001), \( N \geq 0 \) status (HR=1.96, 95% CI: 1.42–2.70), high serum carcinoembryonic antigen levels (HR=1.61, 95% CI: 1.13–2.27), and postoperative chemotherapy (HR=0.53, 95% CI: 0.33–0.87) were independently associated with poor OS. The patients were classified into four risk groups according to the nomogram, and the OS was different among the four groups (\( P \)<0.05).

Conclusion: A nomogram was successfully constructed based on a multivariable analysis, and the nomogram can discriminate the OS of patients with NSCLC based on risk categories, but external validation is still necessary.

Keywords: non-small cell lung cancer, survival, prognosis, spirometry, biochemistry

Introduction
Lung cancer is the leading cause of cancer death in the world.1 In China, the incidence and mortality of lung cancer are high, with 733,300 incident cases and 610,200 deaths in 2015.2 Lung cancer can be histologically classified as small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC), and the prognosis differs significantly between the two diseases. NSCLC accounts for about 85% of
all lung cancers,\textsuperscript{1} and the 5-year overall survival (OS) ranges from 73\% for stage IA to 24\% for stage IIIA.\textsuperscript{3}

Surgical resection is the primary treatment strategy for patients with resectable NSCLC. Many factors were suggested to contribute to the OS of patients with NSCLC, including age, clinical stage,\textsuperscript{4} histological type,\textsuperscript{5} chemotherapy,\textsuperscript{6,7} preoperative spirometry parameters such as forced expiratory volume in the first second (FEV1)\textsuperscript{8} and diffusing capacity of the lung for carbon monoxide (DLCO),\textsuperscript{9} systematic inflammation markers such as the Glasgow Prognostic Score (GPS),\textsuperscript{10} neutrophil-to-lymphocyte ratio (NLR),\textsuperscript{11} and platelet-to-lymphocyte ratio (PLR),\textsuperscript{11} and molecular markers such as carcinoembryonic antigen (CEA) levels, cancer antigen (CA)-125, CA-199, Ki-67, and interleukins.\textsuperscript{12-14}

Although prognostic factors have been identified, there is limited literature on prognostic models based, especially in China. Risk stratification of patients is crucial to guide the application of potentially harmful treatments only to the patients who are the most likely to benefit from them, and because it can help the surgeons select patients eligible for complete resection since surgery implies risks.

Hence, this study aimed to build a prediction model based on clinical information, routine physical and blood tests, and molecular markers. We also constructed a nomogram based on the model parameters. Risk stratification cutoffs for patient OS were suggested based on this nomogram.

Methods

Patients

Patients who underwent surgical resection for lung cancer at the Thoracic Surgery Department of Zhongshan Hospital, Fudan University, from 2009 to 2013, were retrospectively analyzed.

The inclusion criteria were: 1) patients confirmed with first-ever NSCLC by postoperative pathology; and 2) underwent radical resection. The exclusion criteria were: 1) history of any cancer (including lung cancer); 2) patients with metastasis before surgery; 3) preoperative radiotherapy or chemotherapy; 4) incomplete data; or 5) ≤6 months of follow-up.

The institutional review board of Zhongshan Hospital (Fudan University China) approved the study (B2018-083). The study was carried out according to the accepted guidelines and the Declaration of Helsinki. The review board waived the need for informed consent.

Data Collection

Clinical information (age, sex, smoking history, family history of cancer, symptoms [cough, hemoptysis, and chest pain], duration of symptoms, surgical type, tumor grade, clinical stage, and postoperative chemoradiotherapy) were collected from the medical charts. The histological type was confirmed by postoperative pathological examination, according to the classification of the World Health Organization.\textsuperscript{15} The pathological stage was determined according to the eighth edition of the TNM classification system from the American Joint Committee of Cancer (AJCC).\textsuperscript{16} Histopathological analysis was performed using the 2015 World Health Organization (WHO) classification of tumors of the lung, pleura, thymus, and heart.\textsuperscript{17}

Information on preoperative spirometry parameters, preoperative blood tests, and molecular markers (including forced vital capacity FEV1\%, DLCO, creatinine clearance rate [CCR], PLR, CEA, CA19-9, and Cyfra21-1) were extracted from a customer-designed computer-aided software, which is prospectively maintained by research staff. The data were double-entered and stored in the software within 48 h of examination. A unique identifier matched the patients included in the present study, and the corresponding data were exported from the database.

Postoperative Treatment and Follow-Up

Patients were routinely followed every 2–3 months during the first year after surgery, and every 3–6 months after that. At each postoperative hospital visit, chest computed tomography (CT) was routinely performed. OS was calculated from the time of surgery to the date of death. The first-grade relatives of the patients identified deaths and date of death. The patients still alive by June 30th, 2017, were censored.

Statistical Analysis

Statistical analyses were performed using STATA 11.2 (StataCorp, Houston, TX, USA) and R 3.4.3 (R Foundation for Statistical Computing). Univariable and multivariable Cox proportional hazards regression analyses were used, with backward variable selection at P<0.10 to identify the variables retained in the final multivariable model. Prediction models for OS were constructed based on all the retained variables. The Akaike information criterion (AIC) was used to determine the structure of the final prediction model. The Harrell’s C index (also called area under curve (AUC))\textsuperscript{18} was used to evaluate the model’s performance in terms of
discriminative ability. Comparisons were made using the approach by Kang et al\textsuperscript{19} and using the decision curve analysis (DCA) between the full multivariable model and the clinical model, including clinical stage and histological type. The calibration curves for the full multivariable model were generated at 3 and 5 years after surgery. The observed vs the expected probabilities of survival were determined using the bootstrapping method with 1000 replicates in the “rms” R package.

A nomogram was established based on the coefficients of the full multivariable model. To use the nomogram, a patient’s clinical values are located on each axis of each variable, and a line is drawn upwards to determine the number of points received for each variable value. The sum of these numbers is located on the total points axis, and the patient is stratified according to the summed score. The Kaplan-Meier method was used to generate the survival curves, and the log rank test was used for analysis.

All tests were two-sided, and the significance level was set to P<0.05 unless otherwise specified.

**Results**

**Characteristics of the Patients**

A total of 1951 pathologically-diagnosed NSCLC patients underwent surgical resection between 2009 to 2013. Of these patients, 88 had metastatic lesions, R1 or R2 resection was achieved in 463 patients, 768 patients had incomplete clinical information or test results, 262 patients had <6 months of follow-up, and two were finally diagnosed with adenocarcinoma in situ. Therefore, 368 NSCLC patients with R0 resection were included (Figure 1).

The characteristics of the included patients are shown in Table 1. The median follow-up was 51.0 months (interquartile range, 27.0–67.0 months). A total of 188 (50.7%) patients died during follow-up. The 1-, 3-, and 5-year survival rates were 95.7%, 68.2%, and 51.2%, respectively (Table 2).

**Risk Factor Analysis**

The final multivariable model indicated that low DLCO (HR=1.66, 95% CI: 1.18–2.34, P=0.004), high PLR (HR=1.42, 95% CI: 1.04–1.95, P=0.028), histology type of squamous cell carcinoma and others (squamous cell carcinoma vs adenocarcinoma, HR=1.40, 95% CI: 1.01–1.96, P=0.046; others vs adenocarcinoma, HR=2.36, 95% CI: 1.15–4.84, P=0.019), N>0 status (HR=1.96, 95% CI: 1.42–2.70, P<0.001), high serum level of CEA (HR=1.61, 95% CI: 1.13–2.27, P=0.008) and postoperative chemotherapy (HR=0.53, 95% CI: 0.33–0.87, P=0.012) were independently associated with poor OS of NSCLC patients (Table 3).

**Prediction Model Building, Validation, and Calibration**

For the discrimination of patient survival at 3 years, the final multivariable Cox model (full model) reached an AUC of 0.720 (95% CI: 0.658–0.782), which was similar to the clinical model with only clinical stage and histological type (AUC=0.670, 95% CI: 0.607–0.733, Figure 2A). For the discrimination of patient survival at 5 years, the full model reached an AUC of 0.712 (95% CI: 0.649–0.775), which was also similar to the clinical model (AUC=0.647, 95% CI: 0.582–0.711, Figure 2B). The decision curve analysis showed that the full prediction model had a higher net benefit compared with the clinical model for OS at 3 or 5 years (Figure 3).

The calibration analysis for the full model was performed using the bootstrapping method, and the calibration curves showed that the observed proportion of OS and model-predicted OS at 3 and 5 years after surgery were consistent (Figure 4).

**Nomogram for the Full Model and Risk Stratification**

We constructed a nomogram based on the structure and coefficients of the prediction model. The total nomogram score of each of the 368 patients was calculated. Score 0–99 was classified as low risk, 100–199 was moderate risk, 200–299 was moderate-high risk, and ≥300 was high risk (Figure 5). The Kaplan-Meier survival analysis showed that the OS was significantly different among these four groups of patients (P<0.001) (Figure 6).
In this study, we established a nomogram for the OS of NSCLC patients with R0 resection in China. The nomogram was based on an internal validated and calibrated prediction model built using the data from 368 NSCLC patients treated in 2009–2013. The nomogram showed a higher discrimination ability and higher net benefit than the commonly used clinical stage and histological type. To our knowledge, this is the first study evaluating the integrated prediction ability of previously identified prognostic factors on the OS of NSCLC patients with R0 resection in China.

Table 1 Characteristics of 368 NSCLC Patients, 2009–2013

| Variables                                      | n (%)    |
|------------------------------------------------|----------|
| Age, n (%)                                      |          |
| <65 years                                       | 244 (66.3)|
| ≥65 years                                       | 124 (33.7)|
| Sex, n (%)                                      |          |
| Female                                          | 138 (37.5)|
| Male                                            | 230 (62.5)|
| Smoking history, n (%)                         | 102 (27.7)|
| Family history of cancer, n (%)                 | 2 (0.5)  |
| Duration of symptoms, n (%)                    |          |
| <1 year                                         | 172 (46.7)|
| ≥1 year                                         | 196 (53.3)|
| Kidney dysfunction (CCR ≤60 mL/min), n (%)      | 10 (2.7) |
| FEV1%, n (%)                                    |          |
| ≥80%                                            | 237 (64.4)|
| <80%                                            | 131 (35.6)|
| DLCO, n (%)                                     |          |
| ≥20                                             | 133 (36.1)|
| <20                                             | 235 (63.9)|
| Platelet-lymphocyte ratio (PLR), n (%)          |          |
| <150                                            | 227 (61.7)|
| ≥150                                            | 141 (38.3)|
| CEA, n (%)                                      |          |
| <5 µL/mL                                        | 260 (71) |
| ≥5 µL/mL                                        | 106 (29) |
| CA19-9, n (%)                                   |          |
| <37 U/mL                                        | 297 (80.7)|
| ≥37 U/mL                                        | 24 (6.5) |
| Missing data                                    | 47 (12.5)|
| Cyfra21-1, n (%)                                |          |
| <30 ng/mL                                       | 315 (85.6)|
| ≥30 ng/mL                                       | 3 (0.8)  |
| Missing data                                    | 50 (13.6)|
| Surgery, n (%)                                  |          |
| Pneumonectomy & Partial pneumonectomy           | 27 (7.3) |
| Lobectomy                                       | 341 (92.7)|
| Pathology, n (%)                                |          |
| Adenocarcinoma                                  | 226 (61.4)|
| Squamous cell carcinoma                         | 130 (35.3)|
| Others*                                         | 12 (3.3) |
| Tumor grade, n (%)                              |          |
| I                                               | 3 (0.8)  |
| II                                              | 196 (53.4)|
| III                                             | 168 (45.8)|
| Pathological stage, n (%)                       |          |
| I                                               | 202 (54.9)|
| II                                              | 59 (16.0) |

(Continued)

Table 2 Overall Survival of 368 NSCLC Patients with R0 Resection, 2009–2013

| Overall Survival | n (%)    |
|------------------|----------|
| 1-year           | 95.7     |
| 3-year           | 68.2     |
| 5-year           | 51.2     |

*Others: five adenosquamous carcinomas, one sarcomatoid carcinoma, one carcinoid, three large cell carcinoma, and two mucinous epidermoid carcinomas.

Abbreviations: CCR, creatinine clearance rate; FEV1%, forced vital capacity; DLCO, diffusing capacity of the lung for carbon monoxide; CEA, carcinoembryonic antigen; CA19.9, cancer antigen 19.9; Cyfra21-1, cytokeratin 21-fragment.

Discussion

In this study, we established a nomogram for the OS of NSCLC patients with R0 resection in China. The nomogram was based on an internal validated and calibrated prediction model built using the data from 368 NSCLC patients treated in 2009–2013. The nomogram showed a higher discrimination ability and higher net benefit than the commonly used clinical stage and histological type. To our knowledge, this is the first study evaluating the integrated prediction ability of previously identified prognostic factors on the OS of NSCLC patients with R0 resection in China.
Table 3 Factors Associated with the Survival of 368 NSCLC Patients, 2009–2013

| Variables                        | Univariable Cox Regression Analysis | Multivariable Cox Regression Analysis* |
|----------------------------------|------------------------------------|---------------------------------------|
|                                  | Hazard Ratio | 95% CI | p-value | Hazard Ratio | 95% CI | p-value |
| **Age**                          |            |        |        |             |        |        |
| <65 years                        | Ref        | –      | –      |             | –      | –      |
| ≥65 years                        | 1.39       | 1.04, 1.86 | 0.029 |             | –      | –      |
| **Sex**                          |            |        |        |             |        |        |
| Female                           | Ref        | –      | –      |             | –      | –      |
| Male                             | 1.36       | 1.01, 1.85 | 0.047 |             | –      | –      |
| **Duration of symptoms**         |            |        |        |             |        |        |
| <1 year                          | Ref        | –      | –      |             | –      | –      |
| ≥1 year                          | 1.44       | 1.08, 1.93 | 0.014 |             | 1.35   | 0.98, 1.86 | 0.063 |
| **Kidney dysfunction (CCR ≤60 mL/min)** |            |        |        |             |        |        |
| No                               | Ref        | –      | –      |             | –      | –      |
| Yes                              | 1.885      | 0.93, 3.83 | 0.080 |             | –      | –      |
| **FEV1%**                        |            |        |        |             |        |        |
| ≥80%                             | Ref        | –      | –      |             | –      | –      |
| <80%                             | 1.37       | 1.02, 1.83 | 0.034 |             | –      | –      |
| **DLCO**                         |            |        |        |             |        |        |
| ≥20                              | Ref        | –      | –      |             | –      | –      |
| <20                              | 1.39       | 1.02, 1.89 | 0.039 |             | 1.66   | 1.18, 2.34 | 0.004 |
| **Platelet-lymphocyte ratio (PLR)** |            |        |        |             |        |        |
| <150                             | Ref        | –      | –      |             | –      | –      |
| ≥150                             | 1.44       | 1.08, 1.93 | 0.013 |             | 1.42   | 1.04, 1.95 | 0.028 |
| **Pathology**                    |            |        |        |             |        |        |
| Adenocarcinoma                   | Ref        | –      | –      |             | –      | –      |
| Squamous cell carcinoma          | 1.36       | 1.01, 1.84 | 0.041 |             | 1.40   | 1.01, 1.96 | 0.046 |
| Others*                          | 2.83       | 1.48, 5.43 | 0.002 |             | 2.36   | 1.15, 4.84 | 0.019 |
| **Pathological stage**           |            |        |        |             |        |        |
| I                                | Ref        | –      | –      |             | –      | –      |
| II                               | 1.47       | 0.99, 2.2 | 0.057 |             | –      | –      |
| III & IV                         | 2.06       | 1.5, 2.84 | <0.001 |             | –      | –      |
| P trend                          |             |        |        |             |        | <0.001 |
| **Tumor status**                 |            |        |        |             |        |        |
| T1/T2                            | Ref        | –      | –      |             | –      | –      |
| T3/T4                            | 1.19       | 0.81, 1.76 | 0.401 |             | –      | –      |
| **Nodal status**                 |            |        |        |             |        |        |
| N0                               | Ref        | –      | –      |             | –      | –      |
| N>0                              | 1.95       | 1.47, 2.6 | <0.001 |             | 1.96   | 1.42, 2.7 | <0.001 |
| **Distant metastases**           |            |        |        |             |        |        |
| M0                               | Ref        | –      | –      |             | –      | –      |
| M1                               | 0.44       | 0.11, 1.78 | 0.252 |             | –      | –      |
| **Serum level of CEA**           |            |        |        |             |        |        |
| <5 µL/mL                         | Ref        | –      | –      |             | –      | –      |
| ≥5 µL/mL                         | 1.7        | 1.26, 2.29 | 0.001 |             | 1.61   | 1.13, 2.27 | 0.008 |

(Continued)
Despite the rapid development of surgical techniques in the last decade, distinct heterogeneities are still observed among NSCLC patients with R0 resection. Observational studies showed that recurrence might occur as early as 10 months after R0 resection, even with stage IA disease, indicating a poor prognosis. Nevertheless, R0 resection is curative for about 50% of patients with NSCLC, achieving long-term survival. Patients with the same stages of NSCLC or the same histological types may recur or not after complete resection. The most commonly used predictors for patients’ prognosis are the TNM staging system and histological type, but they may have reached the limit of their usefulness to meet the needs for personalized evaluation in the context of precision medicine.

| Variables                  | Univariable Cox Regression Analysis | Multivariable Cox Regression Analysis* |
|----------------------------|------------------------------------|---------------------------------------|
|                            | Hazard Ratio 95% CI p-value        | Hazard Ratio 95% CI p-value            |
| CA19.9                     |                                    |                                       |
| <37 U/mL                   | Ref – 0.96, 2.62 0.074             |                                       |
| ≥37 U/mL                   | 1.58                              |                                       |
| Cyfra21-1                  |                                    |                                       |
| <30 ng/mL                  | Ref – 0.43, 6.98 0.443             |                                       |
| ≥30 ng/mL                  | 1.73                              |                                       |
| Postoperative chemotherapy |                                    |                                       |
| No                         | Ref – 0.42, 0.99 0.045             | Ref – 0.33, 0.87 0.012                |
| Yes                        | 0.65                              | 0.53                                  |
| Postoperative radiotherapy |                                    |                                       |
| No                         | Ref – 0.55, 1.85 0.987             |                                       |
| Yes                        | 1.01                              |                                       |

Notes: *Backward-selection method with a significance threshold of 0.1 was used to identify variables included in the final multivariate model.
Abbreviations: CCR, creatinine clearance rate; FEV1%, forced vital capacity; DLCO, diffusing capacity of the lung for carbon monoxide; CEA, carcinoembryonic antigen; CA19.9, cancer antigen 19.9; Cyfra21-1, cytokeratin 21-fragment.

Figure 2 Performance of prediction models generated from 368 NSCLC patients with R0 resection, 2009–2013. (A) Receiver-operating characteristics (ROC) analysis of the full prediction model (the variables in the full prediction model included duration of symptoms, diffusing capacity of the lung for carbon monoxide, platelet-lymphocyte ratio, serum level of carcinoembryonic antigen, pathology diagnosis, nodal status, and chemotherapy) and simple clinical model (variables in the clinical model included pathology diagnosis and nodal status) for predicting 3-year overall survival. (B) ROC of the full prediction model and simple clinical model for predicting 5-year overall survival.
Previous prediction models were mainly designed from western populations and focused on one or two candidate prognostic factors. Moreover, most prediction models of the survival of patients with NSCLC are presented in the form of receiver operating characteristic (ROC) curves or mathematical formulas, which are not straightforward to the physicians, impairing their application in clinical practice. For example, Dehing-Oberije et al established a prognostic model using blood biomarkers to predict the OS of NSCLC patients and reported that the AUC of the full model consisting of clinical information, CEA levels, and interleukin-6 reached 0.81.25 Another study in China with 320 NSCLC patients showed that the AUCs of PLR and NLR were 0.531 (95% CI: 0.468–0.595) and 0.632 (95% CI: 0.571–0.693), respectively.26 Therefore, it is necessary to establish an accurate, reliable, and easy-to-use prediction model that

Figure 3 Decision curves for the net benefit of the full prediction model (model 2) and clinical model (model 1). (A) Assessment of 3-year overall survival. (B) Assessment of 5-year overall survival.
systematically combines the prediction ability of previously reported factors for the survival of patients with NSCLC.

Here, we present an easy-to-use nomogram for risk stratification of NSCLC patients with R0 resection. The patients were classified into four risk categories, namely low risk (0–99 points), moderate risk (100–199 points), moderate-high risk (200–299 points), and high risk (≥300 points). The 5-year survival for these four groups of patients was 77.7%, 56.5%, 34.9%, and 0%, respectively. The OS of the “low risk” and “moderate risk” groups is better than the average OS, and it could be suggested that these patients should take priority for surgical treatment since they are most likely to benefit from the operation and achieve long-term survival. Caution should be considered for patients who are classified as “moderate-high risk” since they might have a relatively high risk of recurrence. Thus, it is recommended that these patients should have shorter intervals between postoperative follow-up examinations. For “high risk” patients, conservative therapy might be an alternative solution, since no patient achieved long-term survival despite successful operation. Importantly, there was no external validation nor control cohort, and these results have to be taken with caution in the meantime and cannot be used, for now, to modify or guide the clinical practice.
One strength of this study is that we used the decision curve analysis in addition to the AUC to compare the performance between the full multivariable model and the classical clinical model. The AUC focuses on the accuracy of discrimination (i.e., sensitivity and specificity), while the decision curve analysis seeks to maximize the net benefit, which solves the clinical effect problem. In this study, we found that the full prediction model showed a higher net benefit compared with the clinical model across a wide range of threshold probabilities. Additional studies could be performed to verify the value of the full model over the clinical stage and histological type.

We identified a series of previously reported prognostic factors for NSCLC in the 368 patients with R0 resection. The commonly used prognostic variables in clinical settings, the clinical stage, and histological type, demonstrated some degree of prediction ability for OS, but their performance was not robust within the training sample because the internal validation produced an AUC of 0.518, which is very close to a random guess. The additional prognostic factors suggested include the duration of symptoms, DLCO, PLR, serum level of CEA, and CCR. Those variables had additive value for the discrimination of patient OS. Importantly, only a slightly decreased AUC was obtained by the internal validation, suggesting that the increase in model performance is robust within our sample. It should be noted that the selection of predictors in this study was mainly based on statistical association, which does not always mean biological relevance. Besides, potential prognostic factors identified by previous studies were not necessarily observed here. For example, CEA and CCR were included in the final model, but other serum markers such as CA-199 and prognostic factors such as liver dysfunction were excluded.

Lung spirometry was recognized as a critical factor of acute mortality after lung resection in the 1980s and is identified to be a determinant of all-cause mortality in the general population. For NSCLC patients, several studies have reported that FEV1 is an independent risk factor of OS. DLCO is associated with an increased risk of acute morbidity after significant lung resection, but the association between DLCO and OS is controversial. Liptay et al showed that the DLCO is associated with long-term survival after curative lung resection for lung cancer. On the other hand, Wang et al failed to observe such an association. In the present study, DLCO was an independent prognostic factor for the OS of NSCLC patients with R0 resection, which supports the critical role DLCO plays in determining the prognosis of NSCLC patients.

It is well accepted that systemic inflammation plays a crucial role in the carcinogenic process. Convenient systemic inflammatory response indicators such as the GPS (calculated based on the concentrations of C-reactive protein and albumin) have been identified to predict the OS of patients in a variety of cancer types. The NLR and the PLR can be easily estimated based on blood routine examination results and have been proposed to be useful for predicting the prognosis of lung cancer patients. In the present study, we found that PLR ≥150 predicted poor survival among NSCLC patients with R0 resection. The mechanisms explaining this association include: 1) platelets release several kinds of cytokines and growth factors that might affect cell proliferation, migration, and angiogenic activity; 2) tumor cells produce cytokines (e.g., interleukin-6) and expedite the differentiation of bone marrow-derived megakaryocytes to platelets; and 3) the immune evasion process of tumor cells may lead to platelet aggregation.

The CEA is a diagnostic and prognostic marker for cancer. It is widely expressed in a variety of tumors (digestive tract cancers, breast cancer, and urogenital tract cancers), but up-regulation of CEA is not cancer-specific, and high levels of CEA can be detected in non-cancer (e.g., pneumonia) patients. The relatively low sensitivity and specificity of CEA alone in predicting cancer occurrence or patient survival limited its clinical use. Serum CEA levels have been reported to be a prognostic factor and an indicator of recurrence after surgical resection of NSCLC. In the present study, serum CEA ≥5 μL/mL was also found to be an independent risk factor for OS in NSCLC patients with R0 resection. Thus, we think that CEA levels should be used as an adjunct to other predictors to achieve better discrimination in NSCLC patients with R0 resection.

This study has limitations. First, external validation of our prediction model in an independent cohort of patients is needed since we only performed internal validation in the current study. Second, this is a single-center study, and the cutoff values for predictors and risk stratification need to be verified by large-scale multicenter studies.

**Conclusions**

In conclusion, a nomogram was successfully constructed based on a multivariable analysis, and the nomogram can discriminate the OS of patients with NSCLC based on the nomogram’s risk categories. Nevertheless, external validation is still necessary, but external validation is still required.
Abbreviations
NSCLC, non-small cell lung cancer; OS, overall survival; FEV1, forced expiratory volume in the first second; GPS, Glasgow Prognostic Score; CEA, carcinoembryonic antigen; AJCC, American Joint Committee of Cancer; WHO, World Health Organization; CT, computed tomography; AIC, Akaike information criterion; AUC, area under curve; DCA, decision curve analysis.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
3. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–714. doi:10.1097/JTO.0b013e31803182f3
4. Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society Of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(30):3484–3515. doi:10.1200/JCO.2017.74.6065
5. Rinaldi S, Berardi R. Lung cancer prognosis: can histological patterns and morphological features have a role in the management of lung cancer patients? Ann Transl Med. 2017;5(17):353. doi:10.21037/atm
6. Tamura T, Kurishima K, Nakazawa K, Ishikawa H, Satoh H, Hizawa N. Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer. Oncol Lett. 2015;10(2):1135–1140. doi:10.3892/ol.2015.3350
7. Sanz Rubiales A, Del Valle Rivero ML, Fiorini Talavera AB, Fernandez Gonzalez M. Platinum derivatives alone, a reasonable option to treat locally advanced non-small cell lung cancer with chemo-radiotherapy. Lung Cancer. 2015;89(1):84–85. doi:10.1016/j.lungcan.2015.04.013
8. Matsuzaki A, Hashimoto N, Okachi S, et al. Combination of IL-6, IL-10, and C-reactive protein levels as predictive factors for neoadjuvant chemotherapy response in resected stage I NSCLC. Int J Clin Oncol. 2015;20(2):192. doi:10.18632/oncotarget.16127
9. Dehing-Oberije C, Aerts H, Yu S, et al. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiotherapy alone (NCT00815199; NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys. 2011;81(2):360–368. doi:10.1016/j.ijrobp.2010.06.011
10. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–540. doi:10.1016/j.ctrv.2012.08.003
11. Ding N, Pang Z, Shen H, Ni Y, Du J, Liu Q. The prognostic value of PLR in lung cancer, a meta-analysis based on results from a large consecutive cohort. Sci Rep. 2016;6:34823. doi:10.1038/srep34823
12. Kawachi R, Nakazato Y, Takei H, Koshi-ishi Y, Goya T. Clinical significance of preoperative carcinoembryonic antigen level for clinical stage I non-small cell lung cancer: can preoperative carcinoembryonic antigen level predict pathological stage? Interact Cardiol Thorac Surg. 2009;9(2):199–202. doi:10.1510/icvts.2009.206698
13. Maeda R, Suda T, Hachimaru A, Tochii D, Tochii S, Takagi Y. Clinical significance of preoperative carcinoembryonic antigen level in patients with clinical stage IA non-small cell lung cancer. J Thorac Dis. 2017;9(1):176–186. doi:10.21037/jtd
14. Pan YW, Zhou ZG, Wang M, et al. Combination of IL-6, IL-10, and MCP-1 with traditional serum tumor markers in lung cancer diagnosis and prognosis. Genet Mol Res. 2016;15(4). doi:10.4238/gmr.15048949.
15. Shimosato Y. [Histological typing of lung and pleural tumors (3rd edition, 1999): malignant epithelial tumors]. Nihon Roshio. 2002;60 (Suppl 5):123–131.
16. Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a ‘personalized’ approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi:10.3322/caac.21388
17. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 world health organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 2015;10(9):1240–1242. doi:10.1097/JTO.0000000000000663
18. Harrell FE Jr., Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543–2546. doi:10.1001/jama.1982.03320430047030.
19. Lang L, Chen W, Petrick NA, Gallas BD. Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med. 2015;34(4):685–703. doi:10.1002/sim.6370
20. Yamauchi Y, Muley T, Safi S, et al. Dynamic pattern of recurrence in curatively resected non-small cell lung cancer patients: experiences at a single institution. Lung Cancer. 2015;90(2):224–229. doi:10.1016/j.lungcan.2015.09.010
21. Yamashita T, Uramoto H, Onitsuka T, et al. Association between lymphangiogenesis/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer. 2010;70(3):320–328. doi:10.1016/j.lungcan.2010.02.013
22. Palenirn O, Bylicki O, Andre M, et al. Targeted therapy for localized non-small-cell lung cancer: a review. Onco Targets Ther. 2016;9:4099–4104. doi:10.2147/OTT.S104938
23. al-Kattan K, Sepsas F, Fountain SW, Townsend ER. Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg. 1997;12(3):380–384. doi:10.1016/S1010-7940(97)00198-X
24. Pollack JR. A perspective on DNA microarrays in pathology research and practice. Am J Pathol. 2007;171(2):375–385. doi:10.2353/ajpath.2007.070342
25. Dehing-Oberije C, Aerts H, Yu S, et al. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiotherapy alone (NCT00815199; NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys. 2011;81(2):360–368. doi:10.1016/j.ijrobp.2010.06.011
26. Deng M, Ma X, Liang X, Zhu C, Wang M. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer? Oncotarget. 2017;8(23):37200–37207. doi:10.18632/oncotarget.16553
27. Drummond MB, Hansel NN, Connell JE, Scanlon PD, Taskin DP, Wise RA. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(12):1301–1306. doi:10.1164/rcrm.201202-0223OC
28. Fry JS, Hamling JS, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating FEV1 decline to lung cancer risk. BMC Cancer. 2012;12:498. doi:10.1186/1471-2407-12-498
29. de-Torres JP, Marin JM, Casanova C, et al. Identification of COPD patients at high risk for lung cancer mortality using the COPD-LUCSS-DLCO. Chest. 2016;149(4):936–942. doi:10.1378/chest.15-1868
30. Liptay MJ, Basu S, Haaglin MC, et al. Diffusion lung capacity for carbon monoxide (DLCO) is an independent prognostic factor for long-term survival after curative lung resection for cancer. J Surg Oncol. 2009;100(8):703–707. doi:10.1002/(ISSN)1096-9098

31. Wang J, Olak J, Ferguson MK. Diffusing capacity predicts operative mortality but not long-term survival after resection for lung cancer. J Thorac Cardiovasc Surg. 1999;117(3):581–586; discussion 586–587. doi:10.1016/S0022-5223(99)70338-7

32. Koh CH, Bhoo-Pathy N, Ng KL, et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113(1):150–158. doi:10.1038/bjc.2015.183

33. Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a glasgow inflammation outcome study. Br J Cancer. 2011;104(4):726–734. doi:10.1038/sj.bjc.6606087

34. Kinoshita A, Onoda H, Imai N, et al. The glasgow prognostic score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:52. doi:10.1186/1471-2407-13-52

35. Petrelli F, Barni S, Cioni A, et al. The modified glasgow prognostic score and survival in colorectal cancer: a pooled analysis of the literature. Rev Recent Clin Trials. 2015;10(2):135–141. doi:10.2174/1574887110666150317121413

36. Zhang H, Xia H, Zhang L, Zhang B, Yue D, Wang C. Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer. Am J Surg. 2015;210(3):526–535. doi:10.1016/j.amjsurg.2015.03.022

37. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9(2):237–249. doi:10.1111/j.1538-7836.2010.04131.x

38. Sharma D, Brummel-Ziedins KE, Bouchard BA, Holmes CE. Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. J Cell Physiol. 2014;229(8):1005–1015. doi:10.1002/jcp.v229.8

39. Jurazs P, Alonso-Escolano D, Radomski MW. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol. 2004;143(7):819–826. doi:10.1038/sj.bjp.0706013

40. Fiala O, Pesek M, Finek J, et al. Prognostic significance of serum tumor markers in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy. Anticancer Res. 2016;36(1):461–466

41. Zhang ZH, Han YW, Liang H, Wang LM. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer. Cancer Med. 2015;4(11):1633–1638. doi:10.1002/cam4.493

42. Chen F, Yan CE, Li J, Han XI, Wang H, Qi J. Diagnostic value of CYFRA 21-1 and CEA for predicting lymph node metastasis in operable lung cancer. Int J Clin Exp Med. 2015;8(6):9820–9824.